The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study

BACKGROUND AND OBJECTIVE: Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to psychotherapy with placebo. This study estimates potential costs, health...

Descripción completa

Detalles Bibliográficos
Autores principales: Avanceña, Anton L. V., Kahn, James G., Marseille, Elliot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930905/
https://www.ncbi.nlm.nih.gov/pubmed/35230652
http://dx.doi.org/10.1007/s40261-022-01122-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930905/
https://www.ncbi.nlm.nih.gov/pubmed/35230652
http://dx.doi.org/10.1007/s40261-022-01122-0

Ejemplares similares